A Phase III Study of Consolidation Chemotherapy Using UFT plus Cisplatin versus Docetaxel Following Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer

A Phase III Study of Consolidation Chemotherapy Using UFT plus Cisplatin versus Docetaxel Following Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer - A Phase III Study of Consolidation Chemotherapy Using UFT plus Cisplatin versus Docetaxel Following Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000287

Enrollment

150

Registered

2005-11-18

Start date

2003-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced Non-Small Cell Lung Cancer

Interventions

UFT:400mg/m2,p.o.,d1-14,d29-42 Cisplatin:80mg/m2,div,d8,36 Radiation:2Gy*5days/week,d1-40, total 60Gy A: UFT:400mg/m2,p.o.,d1-14 Cisplatin: 80mg/m2,div,d8 every 3-4weeks UFT:400mg/m2,p.o.,d1-1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically or cytologically confirmed NSCLC 2) Measurable or evaluable disease, No prior chemotherapy ,Stage IIIA or IIIB 3) 75 years old or less 4) P.S.(ECOG) 0-1 5)Sufficient organ functions 6)Provided written informed consent.

Exclusion criteria

Exclusion criteria: 1)bronchopulmonary lymph node metastasis 2) Pleural or pericardial effusion requiring treatment 3) Concomitant malignancy 4) Serious concomitant disease 5)Apparent ineterstitial pneumonia or pulmonary fibrosis 6)Pregnant or lactation women, or women with known or suspected pregnancy. Man who wont let to pregnancy

Design outcomes

Primary

Measure	Time frame
Survival	—

Secondary

Measure	Time frame
Response rate, TTP, Safety, Compliance	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026